share_log

Advanced Health Intelligence Signs Binding Term Sheet With Electronic Medical Record and Global Personal Health Record Company OneClinic for Vietnam

Advanced Health Intelligence Signs Binding Term Sheet With Electronic Medical Record and Global Personal Health Record Company OneClinic for Vietnam

高級健康情報部門與電子病歷和越南全球個人健康記錄公司OneClinic簽署具有約束力的條款表
newsfile ·  2023/11/03 17:35

Highlights

亮點

  • AHI signs binding term sheet with OneClinic, an electronic medical record (EMR) and personal health record (PHR) supplier for Vietnam.
  • AHI與越南的電子醫療記錄(EMR)和個人健康記錄(PHR)供應商OneClinic簽署了具有約束力的條款表。
  • OneClinic holds the US Patent and Trademark Office (USPTO) patent for OneEMR and patent-pending for OnePHR, both of which are aligned to interoperable medical standards including FHIR and HL7.
  • OneClinic擁有美國專利商標局(USPTO)的OneEMR專利,OnePHR的專利正在申請中,兩者都符合包括FHIR和HL7在內的可互操作的醫療標準。
  • AHI and OneClinic will initially conduct 5,000 health assessments delivered from mobile screening clinics to validate and further localise for the Vietnamese population.
  • AHI和OneClinic最初將進行5,000份由流動篩查診所提供的健康評估,以驗證越南人群並進一步進行本地化。
  • AHI and OneClinic are targeting 1 million paid users in the first 12 months from commercial launch which is scheduled for Q2-2024.
  • AHI和OneClinic的目標是在計劃於 Q2-2024 上線後的前12個月內有100萬付費用戶。
  • Chronic diseases were responsible for an estimated 81% of total deaths in Vietnam as of 20181
  • 截至2018年,慢性病約佔越南總死亡人數的81%1
  • With a population of approximately 100 million residents, Vietnam is motivated to become a leader of modern health care and unlock the benefits of early detection and intervention for chronic illnesses. AHI's biometric screening and OneClinic's electronic medical records are scalable technologies to help this cause.
  • 越南擁有約1億居民,有動力成爲現代醫療保健的領導者,併發掘慢性病早期發現和干預的好處。AHI的生物識別篩查和OneClinic的電子病歷是可擴展的技術,可以幫助實現這一事業。

South Perth, Australia--(Newsfile Corp. - November 3, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("AHI" or the "Company") wish to inform shareholders that the Company has signed a binding term sheet (BTS) with Vietnam-based OneClinic to integrate AHI's Biometric Health Assessment capabilities into OneClinic's FHIR and HL7 interoperable digital health record system (OneEMR-OnePHR).

澳大利亞南珀斯--(新聞文件公司-2023 年 11 月 3 日)- 高級健康情報有限公司(澳大利亞證券交易所股票代碼:AHI)(納斯達克股票代碼:AHI) (”AHI“或者”公司“)希望告知股東,公司已與總部位於越南的OneClinic簽署了一份具有約束力的條款表(BTS),將AHI的生物識別健康評估功能整合到OneClinic的FHIR和HL7可互操作的數字健康記錄系統(OneEMR-OnePHR)中。

AHI and OneClinic are initially looking to launch a funded research project for 5,000 individuals before commercialising the integrated solution to the broader market. With Vietnam's population of approximately 100 million and the significant prevalence of chronic diseases, there's a pressing need for innovative, scalable healthcare solutions that Vietnam are actively investing to find. Together, leveraging OneClinic's transformative state-of-the-art digital health record system, we'll coordinate to optimise protocols and enhance user engagement strategies. This will pave the way for the successful launch of the comprehensive digital health record OneClinic and AHI biometric health.

AHI和OneClinic最初希望啓動一項針對5,000人的資助研究項目,然後將綜合解決方案商業化到更廣泛的市場。越南人口約爲1億,慢性病患病率高,因此迫切需要創新、可擴展的醫療保健解決方案,越南正在積極投資尋找這些解決方案。我們將共同利用OneClinic的變革性最先進的數字健康記錄系統,進行協調以優化協議並增強用戶參與策略。這將爲成功推出全面的數字健康記錄OneClinic和AHI生物識別健康鋪平道路。

OneClinic, with its guiding principle "For a Healthy Vietnam," has embarked on a transformative journey to digitally engage patients across the entire nation of Vietnam. Launched by the OneClinic Company, this robust digital health platform offers innovative IT solutions for clinic management, making it the nexus between personal health records, clinics, testing centres, pharmacies, and private health insurance agencies. This integrated approach is aimed at revolutionising the patient experience, ensuring convenience, and elevating the standards of medical examination and treatment services.

OneClinic以 “爲了健康的越南” 爲指導原則,已踏上變革之旅,以數字方式吸引整個越南的患者。這個強大的數字健康平台由OneClinic Company推出,爲診所管理提供創新的IT解決方案,使其成爲個人健康記錄、診所、檢測中心、藥房和私人健康保險機構之間的紐帶。這種綜合方法旨在徹底改變患者體驗,確保便利性,並提高體檢和治療服務的標準。

Central to OneClinic's objectives is its state-of-the-art Electronic Medical Record (EMR) system, which has been developed using the patented CLAS Healthcare EMR software, recognised by the US Patent and Trademark Office (USPTO) in 2022. In tandem with this, the platform also boasts the Global Personal Health Record, which is pending a US patent from the USPTO. Together, these tools create a comprehensive and centralised medical database aligned with international interoperable standards, encapsulating a patient's health trajectory from various healthcare facilities.

OneClinic目標的核心是其最先進的電子病歷(EMR)系統,該系統是使用獲得專利的CLAS醫療保健電子病歷軟件開發的,該軟件於2022年獲得美國專利商標局(USPTO)的認可。除此之外,該平台還擁有全球個人健康記錄,該記錄正在申請美國專利商標局的美國專利。這些工具共同創建了一個符合國際互操作標準的全面而集中的醫療數據庫,彙總了來自不同醫療機構的患者健康軌跡。

The synchronous relationship between the Electronic Medical Record and the Global Personal Health Record is at the heart of OneClinic's philosophy.

電子病歷和全球個人健康記錄之間的同步關係是OneClinic理念的核心。

As outlined by Vietnamese-American IT expert Mr. Nguyen Francis Tuan Anh, Director of OneClinic Company, the former is a pivotal tool for doctors. At the same time, the latter empowers patients, particularly those managing chronic diseases, by allowing them to consistently update their health status from the comfort of their homes or wherever else is convenient.

正如越南裔美國人信息技術專家、OneClinic Company董事Nguyen Francis Tuan Anh先生所概述的那樣,前者是醫生的關鍵工具。同時,後者使患者,特別是那些管理慢性病的患者,能夠在舒適的家中或其他方便的地方持續更新健康狀況,從而增強患者的能力。

AHI and OneClinic are set to initiate a research project for 5,000 individuals funded by a combination of NGO's, employers and big pharma as the foundational stage before introducing our integrated solution to the market. This research project is a testament to OneClinic's enduring philosophy, and it will set the stage for a successful and widespread launch of interoperable health and medical records for Vietnam. Together, with AHI's smartphone-derived biometric health assessment we're making strides in healthcare innovation, driven by the guiding principle of 'For a Healthy Vietnam'.

在將我們的綜合解決方案推向市場之前,AHI和OneClinic將啓動一項針對5,000人的研究項目,該項目由非政府組織、僱主和大型製藥公司共同資助,作爲基礎階段。該研究項目證明了OneClinic的經久不衰的理念,它將爲越南成功而廣泛地推出可互操作的健康和醫療記錄奠定基礎。加上AHI的智能手機衍生生物識別健康評估,在 “爲了健康的越南” 的指導原則的推動下,我們在醫療保健創新方面取得了長足的進步。

Mr Francis Nguyen, CEO of OneClinic shares:

OneClinic 股票首席執行官弗朗西斯·阮先生:

Our strategic partnership with AHI, leveraging its smartphone-based biometric assessments, empowers OneClinic to fast-track our ambitions. This collaboration, rooted in best-in-class technology, positions us to seamlessly service, create, and maintain a holistic electronic health record for individuals seamlessly with a medical record for physicians from the vast Vietnamese population-all accessible from the palm of their hand.

我們與AHI的戰略合作伙伴關係,利用其基於智能手機的生物識別評估,使OneClinic能夠快速實現我們的雄心壯志。這種合作植根於一流的技術,使我們能夠爲個人提供無縫服務、創建和維護全面的電子健康記錄,同時爲來自廣大越南人口的醫生提供醫療記錄,所有這些都可以在他們的手掌中查閱。

By harnessing the VMED Group's visionary CICC digital transformation model, OneClinic has crafted niche software capabilities such as OneCIS, OneEMR, and OnePHR, all anchored by the OneHIE database, which complies with international medical standards. Our endeavours in provinces like Khanh Hoa and collaborations like the one with the Hue Family Medicine Centre exemplify our commitment to optimising healthcare models across the nation.

通過利用VMED集團富有遠見的中金數字化轉型模式,OneClinic精心設計了利基軟件功能,例如OneCis、OneEMR和OnePHR,所有這些功能都以符合國際醫學標準的OneHie數據庫爲基礎。我們在慶和省等省份的努力以及與順化家庭醫療中心等省份的合作,體現了我們對優化全國醫療模式的承諾。

Endorsed with the esteemed Sao Khue Award 2023 and backed by testimonials from experts like Dr. Nguyen Minh Tam, Vice Rector of University of Medicine and Pharmacology Hue, OneClinic's digital medical platform stands as a testament to the transformative power of IT in healthcare. Our overarching goal is not just limited to Vietnam; armed with our USPTO patents, we have set our sights on extending our digital health platform outreach to numerous other developing nations.

OneClinic的數字醫療平台獲得了備受推崇的2023年Sao Khue獎的認可,並得到了順化醫藥大學副校長Nguyen Minh Tam博士等專家的證言,證明了IT在醫療保健領域的變革力量。我們的首要目標不僅限於越南;憑藉美國專利商標局的專利,我們已着眼於將數字健康平台的覆蓋範圍擴展到許多其他發展中國家。

In conclusion, OneClinic, fortified by its strategic alliances and relentless drive, is poised to spearhead the digital transformation of patient engagement in Vietnam, embodying its ethos of a healthier Vietnam.

總之,OneClinic憑藉其戰略聯盟和不懈努力,有望帶頭推動越南患者參與度的數字化轉型,體現其更健康的越南精神。

Integrating AHI's advanced health screening in OneClinic's digital health platform.

將 AHI 的高級健康篩查集成到 OneClinic 的數字健康平台中。

OneClinic's ambitious mission to reshape patient health and medical records in Vietnam reaches new heights with our partnership with AHI. By incorporating AHI's state-of-the-art health screening capabilities within mobile technology, we are bringing forth unprecedented accessibility, convenience, and adaptability in population screening.

通過我們與AHI的合作,OneClinic重塑越南患者健康和醫療記錄的雄心勃勃的使命達到了新的高度。通過將AHI最先進的健康篩查功能整合到移動技術中,我們爲人群篩查帶來了前所未有的可及性、便利性和適應性。

Vietnam, with its significant population of approximately 100 million people, presents both challenges and opportunities in healthcare. The facility to access health screenings through widespread tools like mobile phones is a transformative stride in healthcare. Such accessibility ensures that health services can scale swiftly, making inroads even into the most remote corners of the country.

越南擁有約1億人口的大量人口,在醫療保健領域既是挑戰也是機遇。通過手機等廣泛工具進行健康篩查的設施是醫療保健領域的一項變革性進步。這種可及性確保了醫療服務能夠迅速擴展,甚至可以進入該國最偏遠的角落。

More crucially, integrating AHI's technology into OneClinic's platform addresses Vietnam's pressing concern: the escalating prevalence of chronic diseases. By offering universal access to health screenings, we are better positioned to manage and pre-empt chronic conditions, especially among the nation's most vulnerable demographics. With AHI's trailblazing solution at the heart of OneClinic's offerings, we are paving the way for a healthier Vietnam. We are dedicated to ensuring that every individual has the resources and tools they need to take charge of their health well-being.

更重要的是,將AHI的技術整合到OneClinic的平台中可以解決越南的緊迫問題:慢性病患病率的上升。通過普及健康篩查,我們更有能力管理和預防慢性病,尤其是在美國最脆弱的人群中。將AHI的開拓性解決方案作爲OneClinic產品的核心,我們正在爲更健康的越南鋪平道路。我們致力於確保每個人都擁有掌控自己的健康所需的資源和工具。

The AHI biometric health assessment & its synergy with OneClinic EHR in Vietnam

越南的AHI生物識別健康評估及其與OneClinic EHR的協同作用

Vietnam is undergoing a pivotal moment in its demographic transition, marked by a longer lifespan for its inhabitants and consequent increased pressure on health services and income security. The landscape of Vietnam has transformed over the recent decades, characterised by burgeoning urbanisation.

越南正處於人口轉型的關鍵時刻,其特點是居民壽命延長,醫療服務和收入保障的壓力也隨之增加。近幾十年來,越南的格局發生了變化,其特點是城市化的蓬勃發展。

With this shift, exposure to environmental hazards such as air pollution, coupled with lifestyle and dietary changes, has escalated the risk of chronic diseases like diabetes and heart disease, especially among the aging population.

隨着這種轉變,暴露於空氣污染等環境危害,加上生活方式和飲食習慣的改變,增加了患糖尿病和心臟病等慢性病的風險,尤其是在人口老齡化中。

Historically, familial support served as the backbone of healthcare for the elderly in Vietnam. However, with evolving societal patterns, including reduced family sizes and rampant migration, this traditional safety net is vanishing. The healthcare system, although striving, often grapples with challenges like the reducing availability and per capita density of medical professionals, essential medications, and supplies. The divide is evident not only between urban hospitals and rural communities but also in gender disparities in healthcare access. Alarmingly, chronic diseases were responsible for an estimated 81% of total deaths in Vietnam as of 20181.

從歷史上看,家庭支持是越南老年人醫療保健的支柱。但是,隨着社會模式的演變,包括家庭規模的縮小和移民的猖獗,這種傳統的安全網正在消失。醫療保健系統儘管努力奮鬥,但經常面臨諸如醫療專業人員、基本藥物和用品的可用性和人均密度下降等挑戰。這種鴻溝不僅在城市醫院和農村社區之間很明顯,而且在獲得醫療保健方面的性別差異也很明顯。令人震驚的是,截至2018年,慢性病約佔越南總死亡人數的81%1

The AHI Biometric Health Assessment (BHA) technology perfectly aligns with this health crisis. Tailored for mass screenings, AHI's BHA can target Vietnam's substantial population. The BHA's significance lies in its ability to enable early identification of identifiable risks to most of the country's smartphone users for earlier interventions, facilitating not just efficient healthcare budget allocation but also elevating the quality of life for Vietnamese citizens.

AHI 生物識別健康評估 (BHA) 技術完全符合這場健康危機。AHI的BHA專爲大規模篩查量身定製,可以針對越南的大量人口。BHA的重要性在於它能夠及早發現該國大多數智能手機用戶可識別的風險,以便儘早進行干預,這不僅促進了有效的醫療預算分配,還提高了越南公民的生活質量。

Addressing the chronic disease epidemic in Vietnam necessitates a paradigm shift, moving away from solely clinician-based care. It calls for community-centred prevention strategies fortified by digital tools that transition disease management and prevention from medical facilities to homes - all using a smartphone.

應對越南的慢性病疫情需要模式轉變,擺脫僅以臨床爲基礎的護理。它呼籲制定以社區爲中心的預防策略,輔之以數字工具,將疾病管理和預防從醫療機構轉移到家庭——所有這些都使用智能手機。

OneClinic's vision aligns perfectly with this objective. Their primary aim is to identify and support individuals at heightened risk of chronic disease, a move that could radically diminish mortality rates. Their approach is not just humane but also pragmatic, understanding that even a moderate investment in chronic disease prevention can reap substantial economic dividends for Vietnam.

OneClinic的願景與這一目標完全一致。他們的主要目標是識別和支持慢性病風險較高的人,此舉可能會從根本上降低死亡率。他們的做法不僅人道而且務實,他們知道即使對慢性病預防進行適度的投資也可以爲越南帶來可觀的經濟紅利。

The AHI BHA technology is not only efficient but equally convenient, taking just 12 minutes to evaluate 61 parameters, spanning 41 biometrics over five disease risk categories. This assessment is accessible on most smartphones, allowing private evaluations in the comfort of one's home. The synergy with OneClinic's OnePHR platform ensures that this vital data translates into actionable advice for users. This empowers individuals to proactively collaborate with their healthcare providers and the needed interventions to assist them in living healthier, longer lives.

AHI BHA 技術不僅高效,而且同樣方便,僅需 12 分鐘即可評估 61 個參數,涵蓋五個疾病風險類別的 41 個生物識別技術。該評估可在大多數智能手機上訪問,允許在家中舒適地進行私人評估。與OneClinic的OnePHR平台的協同作用確保了這些重要數據轉化爲用戶可操作的建議。這使個人能夠主動與醫療保健提供者合作,並採取必要的干預措施,幫助他們過上更健康、更長壽的生活。

Scott Montgomery, CEO of AHI, said:

AHI首席執行官斯科特·蒙哥馬利說:

"AHI's strategic partnership with OneClinic, demonstrates a commitment to Vietnam's healthcare needs. Our collaboration aims to redefine healthcare accessibility in Vietnam. The statistics are compelling. With chronic diseases accounting for 81% of deaths in 2018 and undoubtedly escalating as it is in the rest of the world, the need for early detection and intervention has never been as intense. The integration of AHI's Biometric Health Assessment into OneClinic's interoperable health records system is an accelerant to that change.

“AHI與OneClinic的戰略合作伙伴關係表明了對越南醫療保健需求的承諾。我們的合作旨在重新定義越南的醫療保健可及性。統計數據令人信服。慢性病佔2018年死亡人數的81%,而且無疑會像世界其他地區一樣不斷升級,因此對早期發現和干預的需求從未像現在這樣強烈。將AHI的生物識別健康評估集成到OneClinic的可互操作的健康記錄系統中是這一變化的加速器。

The convergence of AHI's health screening with OneClinic's digital health and medical records promises unseen accessibility, this will offer immediate healthcare accessibility for nearly 100 million Vietnamese residents. With OneClinic's commitment to a "Healthy Vietnam", this alliance can genuinely impact the growing chronic disease epidemic and further extends AHI's market position as a leading innovator for biometric health screening at population scale.

AHI的健康篩查與OneClinic的數字健康和醫療記錄的融合保證了前所未有的可及性,這將爲近1億越南居民提供即時的醫療保健服務。憑藉OneClinic對 “健康越南” 的承諾,該聯盟可以真正影響日益嚴重的慢性病疫情,並進一步擴大AHI作爲人口規模生物識別健康篩查領先創新者的市場地位。

The exciting thought is we're starting with a population size of 100 million and will expand to neighbouring nations and beyond from here, AHI is proving its incredibly exciting future.

令人興奮的想法是,我們從1億人口規模開始,並將從這裏擴展到鄰國及其他地區,AHI正在證明其令人難以置信的未來。

About OneClinic and VMED Group

關於 OneClinic 和 VMED Group

OneClinic is a renowned subsidiary of VMED Group, a preeminent technology conglomerate deeply rooted in the healthcare sector. Diving deeper into OneClinic reveals its potent digital healthcare platform, designed meticulously to enable patient access to doctors and healthcare networks. This strategic design not only ensures enhanced medical consultations and treatments but also plays a pivotal role in propelling healthcare facilities on their digital transformation journey towards an intelligent, paperless healthcare system.

OneClinic是VMED Group的著名子公司,VMED Group是一家深深扎根於醫療保健領域的卓越科技集團。深入研究OneClinic揭示了其強大的數字醫療平台,該平台經過精心設計,使患者能夠訪問醫生和醫療保健網絡。這種戰略設計不僅可確保加強醫療諮詢和治療,而且在推動醫療機構向智能、無紙化醫療系統邁進數字化轉型過程中發揮着關鍵作用。

Switching our lens to VMED Group, we discover a multifaceted technology conglomerate making significant strides in the healthcare industry. VMED Group's umbrella covers a range of subsidiaries, notably VIETMEDICAL and ONECLINIC. It prides itself on its diverse operational domains, which include the development of avant-garde healthcare IT solutions, the distribution of state-of-the-art medical equipment, the precision-led manufacturing of medical devices, consumables, and supplies, and the tactical execution of specialised investments in the vast healthcare arena.

將目光轉向VMED Group,我們發現一家多元化的科技集團在醫療保健行業取得了長足的進步。VMED 集團的業務範圍涵蓋了一系列子公司,尤其是VIETMEDICAL和ONECLINIC。它以其多樣化的運營領域而自豪,其中包括開發前衛的醫療保健IT解決方案,分銷最先進的醫療設備,以精確爲主導的醫療設備、消耗品和用品的製造,以及在龐大的醫療保健領域進行專業投資的戰術執行。

Steering towards the vision and mission of OneClinic, it emerges as a beacon of digital transformation, ardently striving for the pinnacle of health for the Vietnamese people. Their ground-breaking All-In-One Platform is a testimony to their commitment, offering a comprehensive blend of solutions, including OneCIS, OneEMR, and OnePHR. Central to OneClinic's mission is its drive to sculpt an intelligent, paperless healthcare system, bridging the gap and enhancing connections between patients, doctors, and expansive healthcare networks, all while keeping a vigilant eye on global healthcare evolutions.

它以OneClinic的願景和使命爲導向,成爲數字化轉型的燈塔,熱切地爲越南人民的健康水平而奮鬥。他們開創性的多合一平台證明了他們的承諾,提供了全面的解決方案組合,包括OneCis、OneEMR和OnePHR。OneClinic使命的核心是努力塑造一個智能、無紙化的醫療保健系統,彌合差距,加強患者、醫生和龐大的醫療網絡之間的聯繫,同時密切關注全球醫療保健的發展。

Delving into the core values that steer the conglomerate, it becomes evident that a customer-centric approach reigns supreme. A relentless pursuit of enhancing both preventive healthcare and the broader spectrum of community health underscores their dedication. The intricate balance of delivering unparalleled value is achieved by harnessing the passion, creativity, and unwavering discipline of the collective team.

深入研究指導該集團的核心價值觀,很明顯,以客戶爲中心的方法佔據了至高無上的地位。對加強預防性醫療保健和更廣泛的社區健康的不懈追求凸顯了他們的奉獻精神。通過利用集體團隊的激情、創造力和堅定不移的紀律,可以實現提供無與倫比的價值之間的錯綜複雜的平衡。

OneClinic and VMED Group's professional approach is powered by a dynamic team of experts, engineers, and leading doctors who breathe life into healthcare IT solutions. Their unyielding commitment to staying updated with the latest in technology, international standards, and the ever-evolving legal landscape pertinent to Vietnam's healthcare sector is commendable. This professional ethos is further strengthened by their meticulous planning and the ability to render intuitive interpretations, ensuring customer expectations are met and often surpassed.

OneClinic 和 VMED Group 的專業方法由一支充滿活力的專家、工程師和領先醫生組成的團隊提供支持,他們爲醫療保健 IT 解決方案注入了活力。他們堅定不移地致力於隨時了解與越南醫療保健部門有關的最新技術、國際標準以及不斷變化的法律格局,這值得稱讚。他們精心策劃和直觀解釋的能力進一步強化了這種專業精神,確保滿足並經常超越客戶的期望。

Their pioneering spirit is palpable. Being at the forefront of integrating international standards into healthcare IT solutions in Vietnam, VMED Group is a trailblazer. Their innovation-centric mindset ensures continuous product evolution and the development of bespoke solutions tailored to the unique needs of Vietnamese healthcare. This dedication is reflected in their impressive track record, with digital healthcare solutions seamlessly integrated into renowned establishments like Cho Ray Hospital, Hanoi Obstetrics and Gynaecology Hospital, and several others.

他們的開拓精神是顯而易見的。作爲將國際標準整合到越南醫療保健IT解決方案的最前沿,VMED Group是一家開拓者。他們以創新爲中心的思維方式確保了產品的持續發展和針對越南醫療保健獨特需求量身定製的定製解決方案的開發。這種奉獻精神反映在他們令人印象深刻的往績上,他們將數字醫療解決方案無縫集成到Cho Ray醫院、河內婦產科醫院等知名機構中。

Rounding off their ethos is their unyielding devotion to their clientele. This is manifested in their round-the-clock customer support, paired with their commitment to providing in-depth advice on comprehensive solutions. This dual approach ensures that customers are not only equipped with cutting-edge solutions but also guided on their journey to achieve cost-effectiveness and optimal outcomes.

他們對客戶的不屈不撓的熱愛使他們的精神更加完美。這體現在他們全天候的客戶支持,以及他們就全面解決方案提供深入建議的承諾上。這種雙管齊下的方法可確保客戶不僅獲得最先進的解決方案,還能在旅程中獲得指導,以實現成本效益和最佳結果。

References:

參考文獻:

1

1

For more information, contact:

欲了解更多信息,請聯繫:

Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

斯科特·蒙哥馬
首席執行官
高級健康情報有限公司
E: admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

弗拉多·博薩納克
創始人/戰略主管
高級健康情報有限公司
E: admin@ahi.tech

About Advanced Health Intelligence Ltd

關於先進健康情報有限公司

Advanced Health Intelligence Ltd (AHI) is committed to becoming a global leader in digital health, harnessing its proprietary technology and innovative processes to redefine health screening. Leveraging the ubiquity and convenience of smartphones, AHI aims to deliver a comprehensive suite of assessment tools to healthcare providers, caregivers, insurers, and governments around the world.

Advanced Health Intelligence Ltd(AHI)致力於成爲數字健康領域的全球領導者,利用其專有技術和創新流程來重新定義健康篩查。AHI利用智能手機的普遍性和便利性,旨在爲世界各地的醫療保健提供者、護理人員、保險公司和政府提供一套全面的評估工具。

Our mission is to improve healthcare outcomes, enhance health literacy, and support the early detection and management of various health conditions.

我們的使命是改善醫療保健結果,提高健康素養,並支持各種健康狀況的早期發現和管理。

Since our inception in 2014, AHI has been at the forefront of Health-tech innovation, starting with the world's first on-device body dimensioning capability. Our patented technology has evolved into a robust suite of solutions that symbolise the future of digitised healthcare.

自 2014 年成立以來,AHI 一直處於健康科技創新的最前沿,首先是世界上第一個設備上的人體尺寸測量功能。我們的專利技術已發展成爲一套強大的解決方案,象徵着數字化醫療的未來。

Our key offerings include:

我們的主要產品包括:

  • Body dimension and composition assessments enable the identification of obesity-related comorbidities such as diabetes.
  • Blood biomarker prediction, inclusive of HbA1C, HDL, LDL, and 10-year mortality risk.
  • Transdermal Optical Imaging, providing vital signs and cardiovascular disease risk estimates.
  • On-device dermatological skin identification, capable of recognising 588 skin conditions across 133 categories, including Melanoma.
  • Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.
  • 通過身體尺寸和成分評估,可以識別與肥胖相關的合併症,例如糖尿病。
  • 血液生物標誌物預測,包括HbA1c、HDL、LDL和10年死亡風險。
  • 透皮光學成像,提供生命體徵和心血管疾病風險估算。
  • 設備端皮膚病學識別,能夠識別 133 個類別的 588 種皮膚狀況,包括黑色素瘤。
  • 協助合作伙伴提供個性化的治療和非治療性健康指導,以改善日常習慣並培養健康素養。

At the heart of AHI is our world-class team comprising machine learning and AI experts, computer vision specialists, and medically trained data scientists. Their collective expertise ensures AHI remains at the cutting edge of health-tech innovation, tailoring our technology to meet the evolving needs of our consumers.

AHI 的核心是我們由機器學習和 AI 專家、計算機視覺專家和受過醫學培訓的數據科學家組成的世界一流團隊。他們的集體專業知識確保AHI保持在健康技術創新的前沿,量身定製我們的技術以滿足消費者不斷變化的需求。

AHI's vision extends beyond individual health assessments. We aspire to create a transformative impact at scale, driving forward a new era in digital healthcare. Our biometrically derived triage solution, accessible via a smartphone, enables our partners to identify and manage health risks at a population scale.

AHI的願景不僅限於個人健康評估。我們渴望創造大規模的變革性影響,推動數字醫療的新時代向前發展。我們的生物識別衍生分診解決方案可通過智能手機訪問,使我們的合作伙伴能夠識別和管理人口規模的健康風險。

In pursuing proactive health management, AHI stands ready to guide healthcare providers, caregivers, insurers, and governments in triaging individuals into the most suitable care pathways. Through technology, AHI contributes to a more efficient, effective, and inclusive global healthcare system.

在追求主動健康管理的過程中,AHI隨時準備指導醫療保健提供者、護理人員、保險公司和政府對個人進行分類,選擇最合適的護理途徑。通過技術,AHI爲更高效、更有效和更具包容性的全球醫療體系做出了貢獻。

For more information, please visit: .

想要查詢更多的信息, 請訪問:.

*The Board of Advanced Health Intelligence Ltd has approved this announcement.

*高級健康情報有限公司董事會已批准此公告。

*AHI anticipates that this binding term sheet will not yield immediate revenue. The collaboration with OneClinic is projected to produce minor revenue once the research project is initiated. Correspondingly, AHI foresees more consistent revenue generation following commercial deployment into broader communities throughout Vietnam.

*AHI預計,這份具有約束力的條款表不會立即產生收入。研究項目啓動後,預計與OneClinic的合作將產生少量收入。相應地,AHI預計,在向越南更廣泛的社區進行商業部署後,創收將更加穩定。

Cautionary Note Regarding Forward-Looking Statements:

關於前瞻性陳述的警示說明:

This news release contains information or statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新聞稿包含構成 “前瞻性陳述” 的信息或陳述。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際業績、業績或成就或事態發展與此類前瞻性陳述所表達或暗示的預期結果、業績或成就存在重大差異。前瞻性陳述不是歷史事實,通常但並非總是用 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛力” 和類似表達方式等詞語來識別,或者事件或條件 “將”、“將”、“可能” 或 “應該” 發生。

Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of Advance Health Intelligence, and includes statements about, among other things, future developments and the future operations, strengths, and strategies of Advance Health Intelligence. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

前瞻性信息可能包括但不限於有關Advance Health Intelligence的運營、業務、財務狀況、預期財務業績、業績、前景、機遇、優先事項、目標、目標、持續目標、里程碑、戰略和前景的陳述,還包括有關Advance Health Intelligence未來發展和未來運營、優勢和戰略的陳述。提供前瞻性信息的目的是提供有關管理層當前預期和未來計劃的信息,提醒讀者,此類陳述可能不適合其他目的。這些聲明不應被視爲未來業績或業績的保證。

The forward-looking statements made, or perceived to be made, in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analysis, and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavorable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Advanced Health Intelligence's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

本新聞稿中作出或預計將發表的前瞻性陳述基於管理層的假設和分析以及管理層可能用來得出結論和進行預測或預測的其他因素,包括管理層的經驗以及對歷史趨勢、當前狀況和預期未來發展的評估。儘管管理層認爲,在本新聞稿中發表聲明時,這些假設、分析和評估是合理的,但實際結果可能與任何前瞻性陳述中的預測存在重大差異。可能導致實際業績與前瞻性陳述存在重大差異的風險和因素示例可能包括:監管行動的時機和不可預測性;與其運營或業務相關的監管、立法、法律或其他發展;營銷和銷售能力有限;行業和產品開發的早期階段;產品有限;對第三方的依賴;不利的宣傳或消費者看法;總體經濟狀況和金融市場;競爭加劇的影響;關鍵的損失管理人員;資本要求和流動性;獲得資本的機會;資本支出的時間和金額;COVID-19 的影響;對Advanced Health Intelligence產品的需求和市場規模的變化;專利法改革;專利訴訟和知識產權;利益衝突;以及總體市場和經濟狀況。

The forward-looking information contained in this news release represents the expectations of Advance Health Intelligence as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Advance Health Intelligence undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

本新聞稿中包含的前瞻性信息代表了Advance Health Intelligence截至本新聞稿發佈之日的預期,因此,該日期之後可能會發生變化。讀者不應過分重視前瞻性信息,也不應像其他任何日期一樣依賴這些信息。如果管理層的信念、估計或觀點或其他因素髮生變化,Advance Health Intelligence沒有義務更新這些前瞻性陳述。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論